Harner Mary J, Mueller Luciano, Robbins Kevin J, Reily Michael D
Bristol-Myers Squibb Company, 3551 Lawrenceville Road, Princeton, NJ 08543, United States.
Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT, United States.
Arch Biochem Biophys. 2017 Aug 15;628:132-147. doi: 10.1016/j.abb.2017.06.005. Epub 2017 Jun 13.
The use of NMR as a tool to determine 3 dimensional protein solution structures, once a darling of the pharmaceutical industry, has largely given way to study of the interaction of prospective drugs with macromolecular targets. Many of these approaches involve ligand-centered studies, which have the advantage of speed and efficiency, but there are also many approaches that take directly from our learnings in macromolecular NMR and provide greater structural detail yet are still optimized for rapid turn-around of information. In the evolution of NMR in the pharmaceutical industry, the unique strengths of NMR to provide dynamic and atomic level information continue to be exploited to discover and design new drugs. Numerous methods have been developed over the past two decades that fall into the categories of fragment-based pre-lead discovery, ligand binding studies and qualitative structural screening.
核磁共振(NMR)曾是制药行业的宠儿,作为确定蛋白质溶液三维结构的工具,如今在很大程度上已让位于对潜在药物与大分子靶点相互作用的研究。这些方法中有许多涉及以配体为中心的研究,其具有速度和效率方面的优势,但也有许多方法直接借鉴了我们在大分子NMR方面的知识,能提供更详细的结构信息,并且仍针对信息的快速周转进行了优化。在制药行业NMR的发展过程中,NMR提供动态和原子水平信息的独特优势继续被用于发现和设计新药。在过去二十年中,已经开发出了许多方法,这些方法可分为基于片段的先导化合物发现、配体结合研究和定性结构筛选等类别。